Quantum Dot Probes: Structural Features, Imaging Advantages, and Applications in Tumor Angiogenesis
Quantum Dot Probes: Structural Features, Imaging Advantages, and Applications in Tumor Angiogenesis
Quantum dots are semiconductor nanocrystals that exhibit quantum confinement effects. Their fluorescence wavelength can be adjusted by controlling their composition, particle size, and surface structure. Their relatively narrow emission spectra, strong resistance to photobleaching, and ease of conjugation with antibodies, peptides, or nucleic acid ligands make them suitable for imaging tumor vascular morphology, tracing blood flow, detecting angiogenic targets, and multiplex molecular labeling.
Keywords: quantum dots; fluorescent probes; core–shell structure; NIR-II; tumor angiogenesis; VEGFR2; integrin αvβ3
1 What Are Quantum Dots?
1.1 Basic Definition
Quantum dots (QDs) are generally semiconductor nanocrystals with diameters of approximately 2–10 nm. When their dimensions approach or fall below the exciton Bohr radius of the material, the movement of electrons and holes becomes confined in three dimensions, converting continuous energy bands into size-dependent discrete energy levels. This phenomenon is known as the quantum confinement effect.
1.2 How Quantum Dots Produce Fluorescence
When a quantum dot absorbs a photon with energy greater than its bandgap, an electron is excited from the valence band to the conduction band, leaving a hole in the valence band. The electron and hole form an exciton, which subsequently releases a photon through radiative recombination. A portion of the excitation energy may also be lost through surface defects, lattice vibrations, or nonradiative recombination.
The excitation process can be represented as follows:
Photon absorption → electron–hole pair formation → exciton relaxation → radiative recombination → fluorescence emission
1.3 Why Particle Size Can Regulate Emission Wavelength
Within the same semiconductor material, reducing particle size strengthens the quantum confinement effect and increases the effective bandgap, shifting fluorescence emission toward shorter wavelengths. Increasing particle size decreases the effective bandgap and shifts emission toward longer wavelengths. The emission wavelength of a quantum dot is also influenced by elemental composition, doping, crystal defects, and shell structure and cannot be determined solely from particle size.
1.4 Major Material Types
Material Type | Representative Materials | Major Characteristics | Application Boundaries |
II–VI quantum dots | CdS, CdSe, CdSe/ZnS | Relatively high luminescence efficiency and readily tunable emission wavelengths | Cadmium-containing materials require careful evaluation of ion leakage and long-term toxicity |
I–III–VI quantum dots | CuInS₂, CuInS₂/ZnS | Broad emission range and reduced use of cadmium | Emission peaks are generally broader, and batch-to-batch consistency must be controlled |
Silver chalcogenide quantum dots | Ag₂S, Ag₂Se, AgAuSe | Can cover near-infrared and NIR-II wavelengths | Silver-ion release, surface stability, and in vivo clearance must be evaluated |
Lead chalcogenide quantum dots | PbS | Emission can extend into the NIR-II region | Lead-containing materials are more suitable for optical and materials research; biological applications require rigorous assessment |
Carbon-based quantum dots | Carbon quantum dots and graphene quantum dots | Generally favorable water dispersibility and surface modifiability | Their luminescence mechanisms are not completely identical to those of conventional semiconductor quantum dots |
2 Structural Composition of Quantum Dot Probes
Structural Level | Major Components | Structural Function | Design Considerations |
Luminescent core | CdSe, CdS, CuInS₂, Ag₂S, Ag₂Se, or PbS | Determines the fundamental bandgap and emission range | Control elemental composition, particle size, and crystal defects |
Inorganic shell | Wide-bandgap materials such as ZnS | Passivates surface defects and isolates the luminescent core | Control shell thickness, lattice matching, and structural integrity |
Surface ligands | Thiol-, phosphine-, amine-, or carboxylic acid-based ligands | Stabilize the nanocrystal and provide reactive sites | Prevent ligand detachment, aggregation, and fluorescence quenching |
Hydrophilic protective layer | PEG, amphiphilic polymers, or proteins | Improves water dispersibility and reduces nonspecific adsorption | Control hydrodynamic size, surface charge, and protein corona formation |
Targeting module | Antibodies, peptides, aptamers, or small-molecule ligands | Recognizes vascular endothelial targets | Control conjugation orientation, ligand density, and binding activity |
Functional module | Drugs, photosensitizers, magnetic components, or radioactive groups | Expands therapeutic or multimodal imaging functions | Avoid excessive increases in particle size or interference with quantum dot luminescence |
2.1 Luminescent Core
The luminescent core determines the fundamental spectral range of the quantum dot. CdS, CdSe, or CuInS₂ systems are commonly used for visible-light imaging, whereas narrow-bandgap materials such as Ag₂S, Ag₂Se, AgAuSe, and PbS can be selected for NIR-II imaging.
2.2 Inorganic Shell
The surfaces of quantum dot cores contain undercoordinated atoms and defect energy levels that can capture electrons or holes and enhance nonradiative recombination. Coating the core with a wide-bandgap shell such as ZnS reduces surface defects and improves quantum yield, photostability, and the chemical stability of the core material.
2.3 Hydrophilic Coating and Surface Functional Groups
Quantum dots synthesized in an organic phase are generally stabilized by hydrophobic ligands and cannot be used directly in cellular or animal experiments. Ligand exchange, amphiphilic polymer coating, and PEGylation can transfer them into an aqueous phase while introducing reactive groups such as —COOH, —NH₂, —SH, azide, or alkyne groups onto the surface.
2.4 Target-Recognition Modules
Conjugating anti-VEGFR2 antibodies, RGD peptides, or other vascular-targeting ligands to the quantum dot surface can convert a blood-pool tracer into a molecular probe. An insufficient number of ligands reduces binding capacity, whereas excessive ligand density may increase hydrodynamic size, mask recognition sites, or enhance uptake by the reticuloendothelial system.
3 Imaging Advantages of Quantum Dot Probes
3.1 Spectral Properties and Multiplex Imaging
(1) Broad Absorption and Narrow Emission
Quantum dots can absorb photons over a broad energy range above their bandgap, whereas their fluorescence mainly arises from radiative recombination of band-edge electrons and holes. They therefore generally exhibit broad excitation ranges and relatively narrow emission peaks. Quantum dots with different emission wavelengths can be excited simultaneously under the same or similar conditions and subsequently distinguished according to their respective emission peaks.
(2) Regulation of Emission Wavelength by Size and Composition
The emission wavelength of a quantum dot is jointly determined by its core material, particle size, alloy composition, and core–shell structure. Within the same material system, decreasing particle size generally strengthens quantum confinement and produces a blue shift in emission, whereas altering the semiconductor composition can further expand the tunable wavelength range. Combining quantum dots with different emission wavelengths enables simultaneous labeling of vascular endothelial cells, tumor cells, and other microenvironmental components within the same tissue region.
(3) Practical Advantages of Multicolor Imaging
The advantage of quantum dots in multiplex imaging is not simply the availability of multiple colors. Multiple probes can share the same excitation source while retaining relatively distinct emission channels, reducing conflicts in excitation configurations among different fluorescent probes. Their actual resolving capacity is still affected by emission-peak full width at half maximum, particle-size distribution, detector response range, and spectral crosstalk.
3.2 Fluorescence Brightness and Photostability
(1) Core–Shell Structures Improve Radiative Recombination Efficiency
Undercoordinated atoms on the surfaces of uncoated quantum dots can generate trap states through which electrons or holes are lost by nonradiative processes. Coating the core with a wide-bandgap material such as ZnS can passivate surface defects and restrict carrier migration toward the surface, increasing the proportion of radiative recombination. The actual brightness of a quantum dot depends on its absorption cross-section, quantum yield, crystal quality, and shell integrity rather than solely on its material type.
(2) Resistance to Photobleaching Supports Dynamic Observation
The inorganic crystal and core–shell structures generally provide optimized quantum dots with favorable photostability. Under continuous excitation, they are less susceptible than some organic fluorophores to rapid and irreversible photobleaching. This property makes them suitable for prolonged monitoring of vascular perfusion, blood-flow changes, endothelial-cell migration, and the accumulation of targeted probes along vessel walls.
(3) Stability Does Not Mean Constant Signal Intensity
Quantum dots may still undergo photooxidation, fluorescence blinking, aggregation, and surface-ligand dissociation. Bioconjugation may also alter their surface electronic states and cause fluorescence quenching. Dynamic imaging should therefore monitor fluorescence-intensity changes over time and compare emission peaks, quantum yields, and photostability before and after functionalization.
3.3 Near-Infrared Imaging and Deep-Tissue Vascular Observation
(1) NIR-II Reduces Tissue-Scattering Background
Narrow-bandgap quantum dots such as Ag₂S, Ag₂Se, AgAuSe, and PbS can extend fluorescence emission into the NIR-II region at approximately 1,000–1,700 nm. Within this wavelength range, tissue autofluorescence is relatively low, and light scattering is generally weaker than in the visible and shorter-wavelength near-infrared regions, helping preserve vascular boundaries in deep tissues.
(2) Significance for Tumor Vascular Imaging
The value of NIR-II should not be summarized simply as “deeper penetration.” For vascular imaging, its more important advantage is the reduction of contour broadening caused by tissue scattering, which improves discrimination among adjacent vessels, small branches, and blood-flow boundaries. It can be used to observe tumor vascular networks, microcirculation, and dynamic perfusion.
(3) Emission Wavelength Is Not the Only Determinant
Actual imaging quality is also influenced by quantum yield, excitation wavelength, tissue absorption, detector quantum efficiency, and the optical filter system. Even among NIR-II quantum dots, imaging performance may differ substantially according to material composition and emission wavelength.
3.4 Surface Functionalization and Targeted Imaging
(1) Surface Functional Groups Provide a Basis for Conjugation
Following hydrophilization, carboxyl, amino, thiol, azide, or other reactive groups can be introduced onto quantum dot surfaces. These groups can subsequently be conjugated with recognition molecules such as antibodies, peptides, or aptamers, converting simple fluorescent tracers into targeted molecular probes.
(2) Multivalent Effects Enhance Overall Particle Binding
Multiple targeting ligands can be conjugated to the surface of a single quantum dot. When several ligands simultaneously interact with receptors on the cell membrane, multivalent binding can increase the overall binding strength and local retention of the particle on the target-cell surface. This provides an important structural basis for using quantum dots to image vascular targets such as VEGFR2 and integrins.
(3) Targeted Signals Are Also Influenced by Particle Behavior
Surface modification of quantum dots simultaneously changes their hydrodynamic size, surface charge, protein corona formation, and blood-circulation behavior. In vivo targeted signals depend not only on receptor expression and ligand affinity but also on blood-flow perfusion, vascular permeability, nonspecific uptake, and hepatic and splenic clearance. Local fluorescence intensity cannot therefore be directly equated with target-expression levels.
4 Construction of Targeted Quantum Dot Probes
4.1 Material and Wavelength Selection
Visible-light quantum dots can be selected for confocal cellular imaging and tissue sections. Probes emitting at 650–950 nm can be used for superficial vascular imaging in small animals, whereas NIR-II quantum dots are more suitable for deep-tissue imaging, whole-body blood-flow tracing, and dynamic observation of tumor vasculature. In multicolor experiments, the emission peaks of different quantum dots must be effectively distinguishable by the selected filters and detectors.
4.2 Aqueous-Phase Transfer and PEGylation
Quantum dots synthesized in an organic phase require ligand exchange or amphiphilic polymer coating to obtain water dispersibility. A PEG layer can reduce nonspecific protein adsorption and extend circulation time, but excessively long PEG chains or overly dense PEG coverage may reduce the accessibility of targeting ligands to their receptors.
4.3 Ligand Conjugation
Carboxyl-functionalized quantum dots can be activated using EDC/NHS or EDC/Sulfo-NHS and subsequently coupled to primary amines on antibodies, peptides, or proteins through amide-bond formation. Amino-functionalized quantum dots can react with NHS ester-modified ligands. Maleimide groups can conjugate with thiolated ligands, whereas copper-free click reactions between DBCO and azide groups are suitable for bioconjugation systems that are sensitive to metal catalysts.
4.4 Purification and Quality Control
After conjugation, free ligands should be removed by ultrafiltration, size-exclusion chromatography, or centrifugation. Hydrodynamic size, dispersity, Zeta potential, fluorescence spectra, and ligand loading should then be measured. Cadmium- or lead-containing quantum dots also require evaluation of shell integrity, metal-ion release, and cytotoxicity.
5 Biological Basis of Tumor Angiogenesis
5.1 Tumor Blood Vessel Formation
Continued tumor growth can create hypoxic regions, leading to HIF-1α stabilization and increased expression of pro-angiogenic factors such as VEGF-A. After VEGF-A binds to VEGFR2 on endothelial cells, it activates endothelial-cell proliferation, migration, and vascular sprouting. Basement-membrane degradation, tip-cell selection, stalk-cell expansion, and lumen formation collectively establish the new vascular network.
5.2 Structural Characteristics of Tumor Blood Vessels
Tumor blood vessels are often tortuous, abnormally branched, heterogeneous in diameter, loosely connected at endothelial junctions, and insufficiently covered by pericytes. Blood-flow velocity, perfusion uniformity, and permeability can vary across tumor regions and developmental stages. Fluorescence intensity measured at a single time point cannot fully represent vascular function.
Target or Marker | Biological Localization | Applicable Probes | Major Interpretive Information |
VEGFR2 | One of the principal receptors for pro-angiogenic signaling, with relatively high expression in activated endothelial cells | Anti-VEGFR2 antibody-conjugated quantum dots or VEGF ligand-conjugated quantum dots | Vascular endothelial activation and changes related to VEGF signaling |
Integrin αvβ3 | Participates in endothelial-cell adhesion, migration, and extracellular matrix recognition | RGD peptide-modified quantum dots | Localization of newly formed vessels and migratory endothelial cells |
CD105 | An auxiliary component of the TGF-β receptor complex that can be upregulated in proliferating endothelial cells | Anti-CD105 antibody-conjugated quantum dots | Detection of proliferative tumor vasculature |
CD31 | Endothelial cell-junction-associated molecule | Anti-CD31 antibody-conjugated quantum dots or tissue costaining | Vascular identity, distribution, and microvessel density |
MMP-2/MMP-9 | Participate in basement-membrane and extracellular matrix remodeling | Enzyme-responsive quantum dot probes | Vascular invasion regions and protease activity |
HIF-1α/hypoxic regions | Located upstream of the angiogenic response | Combination of hypoxia-responsive probes and quantum dots | Spatial relationship between hypoxic regions and vascular distribution |
6 Applications of Quantum Dots in Tumor Angiogenesis Research
6.1 Vascular Morphology and Blood-Flow Imaging
After entering the circulation, PEGylated near-infrared quantum dots can function as blood-pool fluorescent tracers for observing tumor vessel boundaries, branching patterns, vessel diameters, and perfusion. Ag₂S quantum dots have been used for real-time blood-flow imaging and imaging of small tumor-associated vessels within the NIR-II window.
6.2 VEGFR2-Targeted Imaging
After conjugation with quantum dots, anti-VEGFR2 antibodies can recognize VEGFR2-expressing endothelial cells. Cellular experiments can detect probe binding to endothelial cells, whereas animal experiments can reveal fluorescence accumulation in tumor vascular regions. Free-antibody competition and nontargeted quantum dot controls are required to exclude passive accumulation.
6.3 Integrin αvβ3-Targeted Imaging
The RGD sequence recognizes integrin αvβ3 and can be used to label regions of active angiogenesis. RGD-modified quantum dots can also be combined with magnetic components to construct fluorescence–magnetic resonance multimodal probes that provide both cellular-scale localization and whole-body anatomical information.
6.4 Multiplex Imaging of the Vascular Microenvironment
Quantum dots with different emission wavelengths can separately label vascular endothelial cells, pericytes, hypoxic regions, and tumor cells under the same excitation light. Spectral unmixing can then be used to analyze the spatial relationships among vascular density, pericyte coverage, and hypoxic distribution while reducing the localization bias caused by serial tissue sectioning.
6.5 Evaluation of Anti-Angiogenic Therapy
Changes in targeted quantum dot signals, vascular branching, perfusion, and permeability can be compared before and after treatment. A decrease in targeted signal may result from reduced target expression, fewer blood vessels, insufficient blood-flow perfusion, or restricted probe delivery and should be interpreted together with immunostaining and functional indicators.
7 Experimental Evaluation and Interpretation of Quantum Dot Probes
Evaluation Stage | Key Indicators | Essential Controls | Result Interpretation |
Optical performance | Emission peak, full width at half maximum, quantum yield, fluorescence lifetime, and resistance to photobleaching | Quantum dots before functionalization | Determines whether shell coating, hydrophilization, and conjugation affect luminescence |
Colloidal stability | Hydrodynamic size, dispersity, Zeta potential, and fluorescence retention | PBS, culture medium, and serum-containing systems | Determines whether aggregation, sedimentation, or fluorescence attenuation occurs |
Cellular targeting | Uptake, membrane localization, intracellular distribution, and colocalization with markers | Nontargeted probe, ligand-competition group, and receptor-blocking or knockdown group | Distinguishes specific binding from nonspecific adsorption |
In vivo imaging performance | Signal-to-background ratio, target-to-background ratio, imaging window, and tissue penetration | Nontargeted probe and equal-dose control | Evaluates vascular recognition capacity and the optimal imaging time |
Tissue distribution | Fluorescence or elemental content in the tumor, liver, spleen, kidneys, and lungs | Pre-administration control and nontargeted probe | Determines tumor accumulation, organ uptake, and in vivo clearance |
Angiogenic phenotype | Microvessel density, branch number, vessel diameter, perfusion, and permeability | Untreated group and anti-angiogenic intervention group | Distinguishes changes in vascular abundance, structure, and function |
Vascular markers | CD31, CD105, VEGFR2, and integrin αvβ3 | Isotype control, target blocking, or genetic intervention | Validates the correspondence between quantum dot signals and target expression |
8 Products
8.1 Visible and Near-Infrared Core–Shell Quantum Dots
Catalog # | Product Name | Grade & Purity/Specifications | Functional Characteristics and Research Positioning |
CdS/ZnS core-shell type quantum dots | PEG functionalized, fluorescence λₑₘ 450 nm, 4 μM in H₂O | Blue emission suitable for the short-wavelength channel in multiplex imaging | |
CdSe/ZnS core-shell type quantum dots | PEG functionalized, fluorescence λₑₘ 520 nm, 4 μM in H₂O | Green emission suitable for fluorescent labeling of cells and tissues | |
CdSe/ZnS core-shell type quantum dots | PEG functionalized, fluorescence λₑₘ 580 nm, 4 μM in H₂O | Orange emission that can be combined with green- and red-emitting quantum dots | |
CdSe/ZnS core-shell type quantum dots | PEG functionalized, fluorescence λₑₘ 620 nm, 4 μM in H₂O | Red emission that helps reduce short-wavelength background interference | |
CdSeS/ZnS alloyed quantum dots | COOH functionalized, fluorescence λₑₘ 630 nm, diameter 6 nm, 1 mg/mL in H₂O | Carboxyl-functionalized surface suitable for EDC/NHS-mediated conjugation with primary amine-containing ligands | |
CdSeS/ZnS alloyed quantum dots | COOH functionalized, fluorescence λₑₘ 665 nm, diameter 6 nm, 1 mg/mL in H₂O | Red emission suitable for constructing antibody- or peptide-conjugated probes | |
Qdot 565 Amino (PEG) Quantum Dots | Ex:300 nm, Em:565 nm, Concentration: 3 mg/mL | Amino- and PEG-functionalized quantum dots suitable for conjugation with carboxylated ligands | |
Qdot 605 Amino (PEG) Quantum Dots | Em:603 nm, Ex:300 nm, Concentration: 3 mg/mL | Red-orange fluorescent probe substrate suitable for multiplex immunolabeling | |
Qdot 705 Amino (PEG) Quantum Dots | Ex:450 nm, Em:702 nm, Concentration: 3 mg/mL | Emission near the near-infrared region suitable for tissue imaging and deep-signal detection | |
Copper Indium Disulfide/Zinc Sulfide Quantum Dots | Peak Emission 550 nm ± 10 nm, QY > 75% | Visible-emitting material system that reduces reliance on cadmium | |
Copper Indium Disulfide/Zinc Sulfide Quantum Dots | Peak Emission 590 nm ± 10 nm, QY > 75% | Orange emission suitable for multicolor cellular labeling | |
Copper Indium Disulfide/Zinc Sulfide Quantum Dots | Peak Emission 630 nm ± 10 nm, QY > 75% | Red emission suitable for tissue-section and vascular labeling | |
Copper Indium Disulfide/Zinc Sulfide Quantum Dots | Peak Emission 800 nm ± 10 nm, QY > 75% | NIR-I emission suitable for superficial vascular imaging in small animals | |
Copper Indium Disulfide/Zinc Sulfide Quantum Dots | Peak Emission 950 nm ± 10 nm, QY > 75% | Emission near the NIR-II boundary suitable for evaluating near-infrared imaging systems |
8.2 Surface-Functionalized Quantum Dots
Catalog # | Product Name | Grade & Purity/Specifications | Functional Characteristics and Research Positioning |
Fluorescent quantum dots | Amino functionalized,Emission wavelength:525 nm,0.05 μmol/L | Amino-functionalized surface suitable for conjugation with carboxylated antibodies, peptides, or linkers | |
Fluorescent quantum dots | Amino functionalized,Emission wavelength:565 nm,0.05 μmol/L | Yellow-green emission suitable for dual or multiplex labeling | |
Fluorescent quantum dots | Amino functionalized,Emission wavelength:585 nm,0.05 μmol/L | Orange emission suitable for labeling cell membranes and proteins | |
Fluorescent quantum dots | Amino functionalized,Emission wavelength:605 nm,0.05 μmol/L | Red-orange emission suitable for developing antibody-conjugated probes | |
Fluorescent quantum dots | Carboxylic functionalized,Emission wavelength:525 nm,0.05 μmol/L | Can be activated by EDC/NHS and conjugated with primary amine-containing ligands | |
Fluorescent quantum dots | Carboxylic functionalized,Emission wavelength:565 nm,0.05 μmol/L | Suitable for conjugation with peptides, antibodies, and proteins | |
Fluorescent quantum dots | Carboxylic functionalized,Emission wavelength:585 nm,0.05 μmol/L | Suitable for constructing orange-emitting targeted quantum dot probes | |
Fluorescent quantum dots | Carboxylic functionalized,Emission wavelength:605 nm,0.05 μmol/L | Suitable for molecularly targeted imaging in the red fluorescence channel | |
CdSe/ZnS Quantum Dots | fluorescence λem 525 nm,8μmol/L in H2O | Aqueous amino-functionalized quantum dots suitable for direct downstream conjugation | |
CdSe/ZnS Quantum Dots | fluorescence λem 600 nm,8μmol/L in H2O | Aqueous red-orange probe substrate | |
CdSe/ZnS Quantum Dots | fluorescence λem 645 nm,8μmol/L in H2O | Long-wavelength red emission suitable for tissue labeling | |
CdSe/ZnS Quantum Dots,COOH functionalized | fluorescence λem 525 nm,8μmol/L in H2O | Aqueous carboxyl-functionalized quantum dots suitable for conjugation with antibodies and peptides | |
CdSe/ZnS Quantum Dots,COOH functionalized | fluorescence λem 605 nm,8μmol/L in H2O | Suitable for constructing red-emitting targeted probes | |
CdSe/ZnS Quantum Dots,COOH functionalized | fluorescence λem 625 nm,8μmol/L in H2O | Suitable for tissue-section imaging and vascular target labeling | |
Carboxyl fluorescent quantum dot nanospheres | Particle size:300nm, 10mg/ml in H2O | The relatively large particle size and high surface-loading capacity are suitable for in vitro detection and material-conjugation evaluation |
8.3 NIR-II Quantum Dots
Catalog # | Product Name | Grade & Purity/Specifications | Functional Characteristics and Research Positioning |
Ag2S Oil phase (1200 nm) | — | Oil-phase NIR-II quantum dots that require aqueous-phase transfer before biological imaging | |
Ag2S-COOH (1200 nm) | — | Carboxyl-functionalized NIR-II quantum dots suitable for conjugation with antibodies or peptides | |
Ag2S-PEG-NH2 (1200 nm) | — | PEG- and amino-functionalized quantum dots combining water dispersibility with reactive conjugation sites | |
Pb:Ag2Se QDs | — | Lead-doped silver selenide quantum dots suitable for NIR-II materials and spectroscopic research | |
AgAuSe Oil phase (1000 nm) | — | Emission at the beginning of the NIR-II region, suitable for phase-transfer and material-development studies | |
AgAuSe Oil phase (1120 nm) | — | Oil-phase NIR-II quantum dots suitable for constructing deep-tissue imaging probes | |
AgAuSe QDs | — | AgAuSe material system suitable for investigating near-infrared luminescence properties | |
AgAuSe-COOH (1000 nm) | — | Carboxyl-functionalized surface suitable for EDC/NHS-mediated conjugation | |
AgAuSe-COOH (1120 nm) | — | Suitable for constructing long-wavelength near-infrared targeted probes | |
AgAuSe-PEG-NH2 (1000 nm) | — | PEGylated amino-functionalized quantum dots suitable for aqueous-phase bioconjugation | |
AgAuSe-PEG-NH2 (1120 nm) | — | Suitable for developing NIR-II targeted imaging probes | |
PbS Quantum Dots | fluorescence λem 1120 nm, stabilized with octadecylamine ligands | Oil-phase NIR-II quantum dots suitable for phase-transfer and spectroscopic research | |
PbS Quantum Dots | fluorescence λem 1250 nm, stabilized with octadecylamine ligands | Suitable for evaluating detectors and imaging systems operating at 1,250 nm | |
PbS Quantum Dots | fluorescence λem 1330 nm, stabilized with octadecylamine ligands | Emit within a longer-wavelength NIR-II region with relatively reduced tissue scattering | |
PbS Quantum Dots | fluorescence λem 1420 nm, stabilized with octadecylamine ligands | Suitable for long-wavelength NIR-II materials and deep-tissue imaging research | |
PbS Quantum Dots | fluorescence λem 1520 nm, stabilized with octadecylamine ligands | Suitable for evaluating NIR-IIb spectroscopy and imaging platforms |
8.4 Products for Quantum Dot Probe Conjugation
Catalog # | Product Name | Grade & Purity/Specifications | Functional Characteristics and Research Positioning |
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride | ≥98% | Activates carboxyl groups on quantum dot surfaces and promotes amide-bond formation with primary amines | |
N-Hydroxysuccinimide (NHS) | ≥98% | Forms an NHS active ester in combination with EDC and improves carboxyl-to-amine conjugation efficiency | |
N-Hydroxysulfosuccinimide sodium salt | ≥98% | A water-soluble activation auxiliary reagent suitable for quantum dot conjugation in buffer | |
Maleimide PEG NHS, MAL-PEG-NHS | MW 2000 Da | The NHS terminus reacts with primary amines, whereas the maleimide terminus reacts with thiolated ligands | |
DBCO-PEG4-NHS Ester | ≥95% | The NHS terminus modifies amino-containing molecules, whereas the DBCO terminus undergoes copper-free click conjugation with azide groups | |
D-Biotin N-Succinimidyl Ester | ≥98% | Conjugates biotin to primary amine-containing antibodies, proteins, or quantum dot surfaces |
Quantum dot probes can image tumor vascular architecture, blood-flow perfusion, and angiogenic molecules through emission-wavelength regulation, core–shell passivation, surface hydrophilization, and targeting-ligand conjugation. Practical applications require simultaneous control of optical stability, targeting specificity, tissue distribution, and material safety, with results interpreted in combination with histological and vascular functional indicators.
References
[1] Tripathi SK, Kaur G, Khurana RK, Kapoor S, Singh B. Quantum Dots and Their Potential Role in Cancer Theranostics. Crit Rev Ther Drug Carrier Syst. 2015;32(6):461-502.
[2] Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater. 2005;4(6):435-446.
[3] Hong G, Robinson JT, Zhang Y, Diao S, Antaris AL, Wang Q, Dai H. In vivo fluorescence imaging with Ag₂S quantum dots in the second near-infrared region. Angew Chem Int Ed Engl. 2012;51(39):9818-9821.
[4] Song C, Zhang Y, Li C, Chen G, Kang X, Wang Q. Enhanced Nanodrug Delivery to Solid Tumors Based on a Tumor Vasculature-Targeted Strategy. Adv Funct Mater. 2016;26(23):4192-4200.
For more related articles, please see below:
[1] Fluorescent probes – brightening the horizon of biomedical research
[2] Calcium Ion Fluorescent Probes: Principles, Classification, and Recent Advances
[3] Fluorescent Probes - Absorption and Fluorescence
[4] Enzyme Probes
